Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia

Aims Familial hypercholesterolaemia (FH) is an autosomal dominant disease that warrants early diagnosis to prevent premature cardiovascular disease (CVD). However, genetic testing to make a definite diagnosis is costly, and careful selection of eligible subjects is important. Unfortunately, accuracy of current diagnostic criteria is poor, especially in young individuals. We therefore developed and validated a model to predict the presence of an FH causing mutation in persons referred by general practitioners. Methods and results All participants in the Dutch FH screening programme from 1994 to 2014 were included in the development cohort. The validation cohort consisted of consecutive patients, suspected for FH, attending the outpatient lipid clinic in Saguenay (Quebec) from 1993 to 2014. Cross-sectional data were available on medical history, lipid profile, and DNA analysis. Multivariable logistic regression analysis was used for model development. The primary outcome was the presence of a deleterious FH mutation. The development cohort comprised 26 167 FH patients and 37 939 unaffected relatives. Our final model included age; sex; levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglycerides; history and age of CVD; use of statins; smoking; alcohol; and presence of hypertension. The area under the receiver operating characteristic curve (AUC) was 85.4% (95% CI: 85.0-85.9). The calibration slope was 1.02 (where 1.00 is optimal). In the validation cohort (1436 FH patients and 1767 unaffected persons), the AUC was 95.4% (95% CI: 94.7-96.1%) and the calibration slope 1.06. Conclusion Our model showed good discrimination and calibration. We specifically expect our model to be of added value for young persons set against current diagnostic criteria, since LDL-C and age are now used as continuous predictors. The equation will be available as an online calculator to estimate the probability of the presence of an FH mutation in individual patients. This tool might aid physicians in the decision for referral of patients for molecular testing.

[1]  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[2]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[3]  J. Kastelein,et al.  Early statin therapy restores endothelial function in children with familial hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[4]  Ewout W Steyerberg,et al.  Internal and external validation of predictive models: a simulation study of bias and precision in small samples. , 2003, Journal of clinical epidemiology.

[5]  T. Farag,et al.  Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.

[6]  J. Kastelein,et al.  The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.

[7]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[8]  L Tiret,et al.  Reliability of reported family history of myocardial infarction. , 1993, BMJ.

[9]  A. Gotto,et al.  Recommendations for the treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis of the American Heart Association. , 1984, Arteriosclerosis.

[10]  J. R. González-Juanatey,et al.  Diagnóstico y tratamiento de la hipercolesterolemia familiar en España: documento de consenso , 2015 .

[11]  E. Sijbrands,et al.  HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA IN THE NETHERLANDS: PREVALENCE, GENOTYPE-PHENOTYPE RELATIONSHIP AND CLINICAL OUTCOME , 2014 .

[12]  H. Büller,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[13]  S. Humphries,et al.  Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic , 2013, Atherosclerosis.

[14]  E. Sijbrands,et al.  Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. , 2009, Atherosclerosis.

[15]  J. Després,et al.  Rapid restriction fragment analysis for screening four point mutations of the Low‐density lipoprotein receptor gene in French Canadians , 1995, Human mutation.

[16]  J. Kastelein,et al.  Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. , 2004, Seminars in vascular medicine.

[17]  J. Kai,et al.  Availability and Quality of Coronary Heart Disease Family History in Primary Care Medical Records: Implications for Cardiovascular Risk Assessment , 2014, PloS one.

[18]  J. Kastelein,et al.  Diagnosis and treatment of familial hypercholesterolaemia. , 2013, European heart journal.

[19]  G. Bedogni,et al.  Clinical Prediction Models—a Practical Approach to Development, Validation and Updating , 2009 .

[20]  O. Faergeman,et al.  The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. , 2005, Atherosclerosis.

[21]  S. Humphries,et al.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study , 2008, European heart journal.

[22]  S. Humphries,et al.  Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. , 2003, Journal of public health medicine.

[23]  Yvonne Vergouwe,et al.  Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. , 2005, Journal of clinical epidemiology.

[24]  E. Barrett-Connor,et al.  Family history of heart attack as an independent predictor of death due to cardiovascular disease. , 1984, Circulation.

[25]  M. Trip,et al.  Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in the Netherlands , 2000, Clinical genetics.

[26]  Roger A. Sugden,et al.  Multiple Imputation for Nonresponse in Surveys , 1988 .

[27]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[28]  F. Labrie,et al.  Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. , 1987, Metabolism: clinical and experimental.

[29]  A. Kessling,et al.  Identification of a second “French Canadian” LDL receptor gene deletion and development of a rapid method to detect both deletions , 1989, Clinical Genetics.

[30]  J. Kastelein,et al.  Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. , 2014, JAMA.

[31]  J. Lindemans,et al.  Evaluation of the Cholestech L.D.X. desktop analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood. , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[32]  G. Watts,et al.  Genetic analysis of familial hypercholesterolaemia in Western Australia. , 2012, Atherosclerosis.

[33]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[34]  J. Kastelein,et al.  Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. , 2012, European heart journal.

[35]  J. Kastelein,et al.  Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. , 2014, Atherosclerosis.

[36]  Andrew B. Kirke,et al.  Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. , 2014, Heart, lung & circulation.

[37]  J. Jukema,et al.  [The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board]. , 2006, Nederlands tijdschrift voor geneeskunde.